Somatostatin Receptor Imaging in Cardiac Sarcoidosis

NCT02812849 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-10-14

No results posted yet for this study

Summary

The purpose of the trial is to determine the accuracy of Cu-64 labelled DOTATATE for diagnosing cardiac sarcoidosis using PET/CT or PET/MRI.

Conditions

  • Cardiac Sarcoidosis

Interventions

DRUG

Cu-64 DOTATATE

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Rasmus S Ripa, MD, DMSc · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-11-30
Completion
2020-02-27

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02812849 on ClinicalTrials.gov